ABBOTT GMBH ARCHITECT ANTI-HBC II REAGENT KIT; TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)
|
Back to Search Results |
|
Catalog Number 08L44-25 |
Device Problem
False Negative Result (1225)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 09/22/2023 |
Event Type
malfunction
|
Event Description
|
The customer reported a false nonreactive architect anti-hbc ii result on a patient.The following results were provided: aug2019 anti-hbc = 8.52 s/co.(b)(6) 2023 anti-hbc = 0.56 s/co; hbsab = 108.76 miu/ml (positive).(b)(6) 2023 anti-hbc = 6.26 s/co; hbsab = 154.06 miu/ml (positive).No impact to patient management was reported.
|
|
Manufacturer Narrative
|
An evaluation is in process.A follow up report will be submitted when the evaluation is complete.This report is being filed on an international product, list number 8l44 that has a similar product distributed in the us, list number 6l22.
|
|
Manufacturer Narrative
|
The evaluation of complaint data for the product and likely cause lot 49777be00 identified normal complaint activity.No customer returns were available for evaluation.Manufacturing documentation for the likely cause lot did not identify any issues associated with the complaint issue.The performance of the likely cause lot was investigated by completing a review for non-conformances, potential non-conformances and deviations related to the likely cause lot.This review did not identify any non-conformances, potential non-conformances, or deviations.As part of the complaint overall investigation, an evaluation of lot 49777be00 clinical sensitivity was performed which demonstrated acceptable sensitivity per specifications, confirming that this lot is meeting the architect anti-hbc ii product requirement.A review of the product labeling concluded that the issue is sufficiently addressed.No systemic issue or product deficiency was identified.
|
|
Event Description
|
The customer reported a false nonreactive architect anti-hbc ii result on a patient.The following results were provided: aug2019 anti-hbc = 8.52 s/co.22sep2023 anti-hbc = 0.56 s/co; hbsab = 108.76 miu/ml (positive).12oct2023 anti-hbc = 6.26 s/co; hbsab = 154.06 miu/ml (positive).No impact to patient management was reported.
|
|
Search Alerts/Recalls
|
|
|